Akebia - International Biopharmaceutical Industry

Current Edition

Issue 9, Volume 3

Current Features

Issue 9, Volume 3

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

news

Akebia to lay off 42% of workforce, suspend trials after FDA drug rejection

Dive Brief: Akebia Therapeutics will lay off 42% of its workforce after the Food and Drug Administration last month rejected its most advanced experimental drug, a...

11 April 2022 news Akebia | Drug

Continue Reading →

news

FDA rejects Akebia drug, dealing another blow to anemia pills

Dive Brief: The Food and Drug Administration rejected an Akebia Therapeutics' anemia pill vadadustat, the company announced Wednesday, over concerns the drug isn't...

1 April 2022 news Akebia | anemia

Continue Reading →